ELTP - Elite Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.09
+0.00 (+1.01%)
As of 10:59AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.09
Open0.09
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.09 - 0.09
52 Week Range0.06 - 0.14
Volume261,037
Avg. Volume898,460
Market Cap72.911M
Beta1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.01
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Elite Pharmaceuticals Files ANDA for Codeine and Acetaminophen Combo

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/7.5mg, 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets.   Acetaminophen with codeine is a combination medication indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Acetaminophen with codeine products have annual U.S. sales of approximately $45 million according to IQVIA (formerly QuintilesIMS Health Data).

  • GlobeNewswirelast month

    Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positive topline results from pivotal bioequivalence studies conducted for an undisclosed immediate-release antibiotic generic product being co-developed with SunGen Pharma.  The topline results indicate that the generic product is bioequivalent to the branded product in both fasted and fed studies. A filing on this product would be our third ANDA filed from our collaboration with SunGen,” said Nasrat Hakim, Chairman and CEO of Elite.

  • ACCESSWIRElast month

    Elite Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 10, 2018 at 11:00 AM Eastern ...

  • GlobeNewswirelast month

    Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2019 Ended June 30, 2018 and Provides Conference Call Information

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2019 ended June 30, 2018 (“First Quarter”). Consolidated revenues for the First Quarter were $2.2 million, an increase of approximately 27% as compared to revenues for the comparable quarter of the prior fiscal year.  The increase in revenues was largely attributed to higher revenues from generic naltrexone and phentermine manufacturing.  Elite continues to invest in product development as $1.3 million was devoted to research and development expenses.  During this fiscal year Elite has received FDA approval for generic Oxycodone/Acetaminophen and generic Methadone.

  • GlobeNewswirelast month

    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2019 Financial Results on August 10, 2018

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the first quarter financial results of the 2019 fiscal year will be released on Thursday, August 9, 2018.

  • GlobeNewswirelast month

    Elite Pharmaceuticals Appoints Aqeel A. Fatmi, Ph.D. to Its Board of Directors

    Dr. Fatmi qualifies as an independent director under the Nasdaq Rules. Dr. Aqeel Fatmi has acquired more than 35 years of experience in the pharmaceutical industry while serving in leadership positions and advisory boards for multiple global companies. Dr. Fatmi has expertise and experience in strategic development, mergers and acquisitions, research and development, supply chain management, operations excellence and business development.

  • GlobeNewswire2 months ago

    Elite Pharmaceuticals Receives FDA Approval for Generic Methadone Hydrochloride Tablets

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Company’s abbreviated new drug application (ANDA) for methadone hydrochloride 5 mg and 10 mg tablets.  Methadone is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate.  Methadone can also be used for maintenance treatment of opioid addiction (heroin or other morphine-like drugs) in conjunction with appropriate social and medical services. Glenmark Pharmaceuticals, Inc., Elite’s marketing alliance partner, will sell and distribute methadone for Elite for which Elite will receive manufacturing and license fees.

  • GlobeNewswire3 months ago

    Elite Pharmaceuticals Receives FDA Approval for Generic Percocet® Tablets

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for generic Percocet® (Oxycodone Hydrochloride and Acetaminophen, USP CII) 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg tablets.  This product is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Based on QuintilesIMS Health data for the twelve months ending May 31, 2018, the retail sales for the brand and generic products were approximately $500 million.

  • ACCESSWIRE7 months ago

    New Research: Key Drivers of Growth for U.S. Stem Cell Inc. and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of U.S. Stem Cell Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ...

  • ACCESSWIRE7 months ago

    Elite Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 12, 2018 at 11:30 AM ...